Calcium and Colorectal Cancer

by Jack Norris, RD

• Summary
• Research review
• Table 1. Cohort studies on calcium and colorectal cancer
• Table 2. RCTs of calcium and colorectal cancer
• Footnotes
• References

Author’s note: For this article, I used AI tools in the literature search, analysis, data extraction, and copyediting. The conclusions reflect my assessment after verifying study details. (Last reviewed: March 2026.)

Summary

Higher calcium intake — ideally around 1,000 mg/day — is consistently associated with lower colorectal cancer risk in observational studies, and the World Cancer Research Fund rates the evidence for causality as “probable.” Randomized trials have been largely disappointing, however, possibly because they’re too short to capture a process that unfolds over decades or because participants already have adequate calcium intakes at baseline. For vegans, who often fall below 700 mg/day, aiming for closer to 1,000 mg/day is worth prioritizing for bone health and could also protect against colorectal cancer.

Research review

Higher calcium intake is consistently associated with lower colorectal cancer (CRC) risk in observational studies (see Table 1 of recent cohort studies and a 2004 meta-analysis). Randomized controlled trials (RCTs) have largely failed to confirm a benefit from supplementation (see Table 2).

The observational case is moderately strong. Across large prospective cohorts totaling hundreds of thousands of participants and more than a decade of follow-up, higher calcium intake is associated with CRC risk reductions of roughly 15–30% comparing high to low intake. The meta-analysis (Cho, 2004) suggests a threshold of about 1,000 mg/day, with little additional benefit above that level. Perhaps the most persuasive evidence for causality comes from the Million Women Study (Papier, 2025, United Kingdom), which used Mendelian randomization, a genetic approach that reduces confounding; they found a 40–51% lower CRC risk associated with higher genetically-predicted (though not directly measured) calcium intake. In their 2018 report, the World Cancer Research Fund and American Institute for Cancer Research conclude that the consumption of dairy products and calcium supplements “probably” protect against CRC.

The RCT picture is less persuasive. The one positive trial (Baron, 1999) found that 1,200 mg/day of supplemental calcium reduced adenoma recurrence by about 19% in people with a recent polyp history (number needed to treat of ~14 to prevent adenoma recurrence over 4 years¹), with a carryover effect persisting up to five years after supplementation ended (Grau, 2007). But a larger follow-up trial using the same dose was null (Baron, 2015), as was the Women’s Health Initiative (WHI) calcium and vitamin D trial in over 36,000 postmenopausal women (Wactawski-Wende, 2006, United States). Notably, participants in the null Baron 2015 trial had mean baseline dietary calcium of only ~672 mg/day, low enough that the 1,000 mg threshold hypothesis would predict a benefit from supplementation. That it didn’t materialize is a meaningful challenge to the idea that supplements can replicate the protection seen in observational data. Note that two of the RCTs (Baron, 1999; Baron, 2015) used adenoma recurrence as their endpoint rather than CRC incidence directly.

Some factors could explain the discrepancy between observational and RCT findings: 1. Trials of 3–7 years may be insufficient given that colorectal carcinogenesis unfolds over decades. 2. At least for the WHI, participants were already health-conscious consumers of calcium-rich diets (1,151 mg/d at baseline), potentially leaving little room for a supplemental benefit to emerge.

The observational data suggest a modest colorectal benefit with a number needed to treat of about 400 over 10 years for an average-risk adult.² For vegans, who often fall below 700 mg/day, ensuring adequate calcium intake to reach ~1,000 mg/day might be more important for bone health, but could also help prevent colorectal cancer.

Table 1. Cohort studies on calcium and colorectal cancer
Study	Design	Population	Results	Adjustments
NIH-AARP Zouiouich, et al., 2025 United States	NIH-AARP Diet and Health Study; prospective cohort; median 18.4 y follow-up (max 23 y, 1995–2018)	471,396 cancer-free adults at baseline; ages 50–71 y (mean 62.0 ± 5.4); 59.5% male; 91.3% non-Hispanic White; 10,618 incident CRC cases during follow-up	Primary outcome: CRC incidence Total Ca (~401–407 vs. ~1,773–2,056 mg/d): HR 0.71 (0.65–0.78) p-trend<.001; Dietary Ca (~1,100–1,400 vs ~363–381 mg/d): HR 0.84 (0.77–0.92) p-trend=.001; Supplemental Ca (≥1,000 vs 0 mg/d): HR 0.80 (0.72–0.90) p-trend<.001; Continuous (per 300 mg/d total Ca): HR 0.92 (0.90–0.95); By tumor site (total Ca, Q5 vs Q1): Proximal colon: HR 0.75 (0.66–0.86) p-trend<.001; Distal colon: HR 0.73 (0.61–0.87) p-trend<.001; Rectal: HR 0.61 (0.51–0.74) p-trend<.001; Sensitivity: Lag analysis (total Ca): inverse association consistent across <5 y, 5–10 y, and >10 y follow-up periods, arguing against reverse causality	Sex, age, race/ethnicity, education, marital status, BMI, family history of cancer, smoking, physical activity, multivitamin, alcohol, whole grains, fruits and vegetables, unprocessed red meat, processed meat, supplemental folate, vit C, vit D, energy; dietary ca models also adjusted for supplemental ca; supplemental ca models also adjusted for dietary ca.
MWS Papier, et al., 2025 United Kingdom	Million Women Study; prospective cohort; mean 16.6 ± 4.8 y follow-up (1996–2018); diet-wide analysis of 97 dietary factors; FDR correction applied (p<0.009 threshold); Mendelian randomization using lactase SNP (rs4988235) in GECCO meta-analysis (99,152 participants, 52,865 cases)	542,778 women; mean age 59.7 ± 4.9 y at dietary assessment; 12,251 incident CRC cases; predominantly European ancestry; mean ca intakes: 980 ± 360 mg; highest quintile ~1,100 mg/d (NR for lowest quintile)	Primary outcome (CRC incidence): Ca (per 300 mg/d): RR 0.83 (0.77–0.89), FDR-corrected p<0.009, second strongest association of 97 dietary factors tested; Dairy milk (per 200 g/d): RR 0.86 (0.81–0.92); Ca vs dairy: Ca independent of dairy milk (LRT p=0.01); Dairy milk not independent of ca (LRT p=0.67); Most dairy-related associations (phosphorus, riboflavin, magnesium, potassium, yogurt) attenuated after ca adjustment; By ca source: no heterogeneity (p-het=0.21); Dairy Q5 vs Q1: RR 0.86 (0.81–0.92); Non-dairy Q5 vs Q1: RR 0.94 (0.86–1.01) Subgrouping: No significant heterogeneity by colorectal subsites Sensitivity: ≥5-year lag, restriction to good/excellent health: findings broadly similar; Mendelian randomization (lactase SNP as proxy for milk intake; effect scaled to 200 g/d higher milk), i.e, people genetically predisposed to drink 200 g/d more milk compared to people without that genetic predisposition: CRC RR 0.60 (0.46–0.74); colon RR 0.60 (0.43–0.77); rectal RR 0.49 (0.31–0.67)	Stratified by birth year, survey date, region; adjusted for area-based deprivation, education, BMI, height, strenuous exercise, dietary energy, alcohol, smoking, HRT use, family history of bowel cancer.
NHS / HPFS Zhang, et al., 2016 United States	Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS); two prospective cohorts pooled; NHS follow-up 1980–2012 (up to 32 y); HPFS follow-up 1986–2012 (up to 26 y); ca assessed by FFQ every 4 y	88,509 women (NHS) and 47,740 men (HPFS); 3,622,835 person-years; NHS baseline age 30–55 y; HPFS baseline age 40–75 y; cumulative average intake used as primary exposure; total ca intake categorized as <600, 600–<800, 800–<1000, 1000–<1200, 1200–<1400, ≥1400 mg/d	Primary outcome (colon cancer, ≥1400 vs. <600 mg/d total Ca): Pooled: RR 0.78 (0.65–0.95) p-trend=0.05A; NHS: RR 0.75 (0.59–0.97) p-trend=0.02A; HPFS: RR 0.83 (0.62–1.09) p-trend=0.43; Colorectal cancer (≥1400 vs. <600 mg/d total Ca): Pooled: RR 0.83 (0.62–1.12) p-trend=0.36; NHS: RR 0.72 (0.58–0.90) p-trend=0.01; HPFS: RR 0.98 (0.76–1.25) p-trend=0.89; By tumor site (pooled, ≥1400 vs. <600 mg/d): Rectal cancer: RR 1.12 (0.51–2.48) p-trend=0.79; HPFS only rectal cancer: RR 1.68 (1.02–2.78) p-trend=0.06 Ca source: Supplementary Table 2 indicates that the most robust finding by ca source and cancer subsite is that both total ca and dairy ca are associated with a reduced risk of distal colon cancer (pooled results of total ca p-trend=.002). Latency testing: Association strongest at 12–16 y lag: pooled RR 0.76 (0.64–0.91) p-trend=0.02A; null at 0–4 y lag; no significant heterogeneity by sex for any lag period. No multiplicity correction stated.	Age, race, BMI, smoking, family history of CRC, sigmoidoscopy/colonoscopy, physical activity, aspirin, alcohol, predicted 25(OH)D score, folate, red meat, processed meat, postmenopausal hormone use; stratified by age and questionnaire year
Meta-analysis Cho, et al., 2004 Multi-country	Pooled analysis of 10 prospective cohort studies; follow-up 6–16 y; exposures: milk, dairy products, dietary ca, total ca (diet + supplements); study-specific quintiles used for ca analyses; energy-adjusted intakes	534,536 participants; 4,992 CRC cases; studies from the United States, Canada, Sweden, and the Netherlands; both sexes	Primary outcome (CRC, Q5 vs. Q1, study-specific quintiles): Dietary Ca: RR 0.86 (0.78–0.95) p-trend=.02 p-heterogeneity=.98 (low heterogeneity); Total Ca: RR 0.78 (0.69–0.88) p-trend<.001 p-heterogeneity=.97 Subgrouping: Dose-response: nonparametric regression suggests threshold ~1,000 mg/day total Ca, with little further risk reduction above that level. Vitamin D interaction: ca significantly protective only in highest tertile of vit D intake (RR 0.72, 0.55–0.92, p-trend=0.04); highest tertiles of both ca and vit D vs lowest for both: RR 0.74 (0.65–0.84).	Age, sex, BMI, smoking, physical activity, alcohol, red meat, dietary folate, multivitamin use (total Ca model only), oral contraceptive use, postmenopausal hormone use.
AFinding vulnerable to multiplicity correction. Abbreviations 25(OH)D = 25-hydroxyvitamin D BMI = body mass index Ca = calcium CRC = colorectal cancer FDR = false discovery rate FFQ = food frequency questionnaire GECCO = Genetics and Epidemiology of Colorectal Cancer Consortium HR = hazard ratio HRT = hormone replacement therapy LRT = likelihood ratio test Q1, Q5 = first and fifth quintiles RR = relative risk SNP = single nucleotide polymorphism

Table 2. RCTs of calcium and colorectal cancer
Study	Description	Population	Dose	Results	Adjustments
Baron et al., 2015 United States	Vit D/calcium polyp prevention study; 3–5 year randomized, double-blind, placebo-controlled trial; partial 2×2 factorial design; 11 academic medical centers	2,259 randomized; ages 45–75 y (mean 58.5 ± 7.0); recent colorectal adenoma removal with no remaining polyps at colonoscopy; 85% male; 36% obese; baseline dietary calcium intake, mean ~650–720 mg/d across arms	1,200 mg Ca/day from calcium carbonate or placebo; 1,000 IU vit D3/day or placebo	Primary outcome (any adenoma recurrence): Vit D vs. no vit D: RR 0.99 (0.89–1.09) p=0.98; Ca vs. no Ca: RR 0.95 (0.85–1.06) p=0.37; Vit D + Ca vs. neither: RR 0.93 (0.80–1.08) p=0.49; Advanced adenomas: similar null findings for all comparisons Subgrouping: Baseline Ca intake (≤597 vs. >597 mg/day): no differential effect of ca supplementation, p=0.55 (any adenoma), p=0.89 (advanced adenoma). BMI (Ca vs. no Ca): BMI <25: RR 0.75 (0.58–0.98); BMI 25–29.9: RR 0.93 (0.78–1.10); BMI ≥30: RR 1.08 (0.91–1.29); p-interaction=0.02.A Ad hoc observation of no-ca intervention: No difference in adenoma risk across quartiles of baseline Ca intake (≥436, 437-597, 598-831, ≥831 mg/d) or per 200 mg/d increase (0.99, 0.93–1.04)	Age, clinical center, anticipated surveillance interval, sex and randomization type, number of baseline adenomas
CPPS Baron, et al., 1999 United States	Calcium Polyp Prevention Study; ~4-year randomized, double-blind, placebo-controlled trial; 3-month placebo run-in prior to randomization; 6 clinical centers	930 randomized; recent colorectal adenoma removal (within 3 mo), entire large bowel examined and free of polyps, age <80 y (mean 61 ± 9); 72% male; baseline dietary Ca ~865–889 mg/d across arms	1,200 mg elemental Ca/d from calcium carbonate (3 g/d), one tablet twice daily with meals	Primary outcome (≥1 adenoma, after year-1 colonoscopy through year-4 colonoscopy): Any adenoma: RR 0.81 (0.67–0.99) p=0.04; Mean number of adenomas (to account for pp developing > 1): ratio to placebo 0.76 (0.60–0.96) p=0.02; Subgrouping: Authors state no modification of the effect of calcium by age, sex, or baseline dietary intake of calcium, fat, or fiber (data not shown). Secondary outcomes: Any adenoma, first study interval (randomization through year 1 colonoscopy): RR 0.78 (0.63–0.96) p=0.02; Any adenoma, either interval combined (n=913 with ≥1 colonoscopy): RR 0.85 (0.74–0.98) p=0.03;	Age, sex, clinical center, lifetime number of adenomas before study entry, length of surveillance period
CPPS follow-up Grau, et al., 2007 United States	Calcium Polyp Prevention Study post-treatment observational follow-up; participants from the CPPS RCT (Baron 1999) were followed for up to 10 years after the end of active supplementation; no re-randomization; colonoscopies per clinical indication or participant initiative; not industry funded but J. Baron received speaker fees.	822 of original 930 CPPS participants (93%) with some post-treatment information; 597 (73%) underwent ≥1 post-treatment colonoscopy; mean age at end of active trial ~65 y; 72% male; baseline dietary Ca not meaningfully different between arms (NR for follow-up period)	No active intervention; analysis based on original randomized assignment to 1,200 mg elemental Ca/d vs. placebo during the prior 4-year CPPS trial	Primary outcome (any adenoma recurrence, post-treatment): Years 0–5 after end of treatment: RR 0.63 (0.46–0.87) p=0.005; Years 5–10 after end of treatment: RR 1.09 (0.85–1.39) p=0.511 Subgrouping: Years 0–5, excluding subjects who initiated Ca supplements during follow-up: RR 0.59 (0.40–0.90); Years 5–10, excluding subjects who initiated Ca supplements during follow-up: RR 1.05 (0.77–1.43)	Age, sex, center, follow-up time, number of colonoscopies from end of active trial to last colonoscopy, calcium supplement use before first post-treatment colonoscopy
WHI CaD Wactawski-Wende, et al., 2006 United States	Women’s Health Initiative Calcium plus Vitamin D; 7-year randomized, double-blind, placebo-controlled trial; CRC was a designated secondary outcome (primary: hip fracture); 40 clinical centers; 60% took ≥80% of pills, stable through year 6	36,282 postmenopausal women; ages 50–79 y; mean follow-up 7.0 ± 1.4 y; baseline total Ca intake: mean 1,151 mg/d	1,000 mg Ca + 400 IU vitamin D3/d from calcium carbonate (in two doses)	Primary outcome for this paper: colorectal cancer Ca+D vs. placebo: HR 1.08 (0.86–1.34) p=0.51, Bonferroni-adjusted p=0.32 Subgrouping: No significant interaction by baseline Ca intake, age, race/ethnicity, BMI, physical activity, smoking, NSAID use, or hormone therapy; Secondary outcomes: Colon cancer: HR 1.00 (0.78–1.28) p=0.99; Rectal cancer: HR 1.46 (0.92–2.32) p=0.11; CRC mortality: HR 0.82 (0.52–1.29) p=0.39; Kidney stones: HR 1.17 (1.02–1.34) p=0.02, likely doesn’t withstand multiplicity correction	Age, history of CRC, assignment in hormone therapy and dietary modification trials. Education, BMI, physical activity, Ca intake, vit D intake, smoking, etc. were similar between randomized groups at baseline.
AVulnerable to multiplicity correction. Abbreviations BMI = body mass index Ca = calcium HR = hazard ratio IU = international units NR = not reported NSAID = non-steroidal anti-inflammatory drug pp = participants RR = relative risk vit D = vitamin D

Footnotes

1. NNT for Baron et al. 1999:

• Placebo recurrence rate: 38% (159/423)
• Calcium recurrence rate: 31% (127/409)
• ARR = 38% − 31% = 7%
• NNT = 1 / 0.07 = ~14

2. NNT for the NIH-AARP cohort (Zouiouich, 2025):

• Baseline 10-year CRC incidence: 10,618 cases / 471,396 participants over 18.4 years = ~1.2% per 10 years
• RRR applied: 20% (reasonable estimate of the observational data)
• ARR = 1.2% × 0.20 = 0.24%
• NNT = 1 / 0.0024 = ~420 over 10 years

The baseline rate is across all calcium intake levels, so the NNT for someone with genuinely low intake may be somewhat lower.

References

Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999 Jan 14;340(2):101-7.

Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo JC, Goodman M, Kim AS, Robertson DJ, Rothstein R, Shaukat A, Seabrook ME, Summers RW. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med. 2015 Oct 15;373(16):1519-30. Supplementary material available.

Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, Gass ML, Jacobs ET, LaCroix AZ, Lane D, Larson J, Margolis KL, Millen AE, Sarto GE, Vitolins MZ, Wallace RB. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women’s Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer. 2011;63(6):827-41.

Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004 Jul 7;96(13):1015-22. doi: 10.1093/jnci/djh185. Erratum in: J Natl Cancer Inst. 2004 Nov 17;96(22):1724.

Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JS. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst. 2007 Jan 17;99(2):129-36.

Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, Bostick RM. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila). 2011 Oct;4(10):1645-54. A smaller mechanistic RCT (n=92), 6 months in patients with a recent adenoma using a 2×2 factorial design: placebo, 2g/day calcium, 800 IU/day vitamin D3, or both. Both calcium and vitamin D3 increased expression of the calcium-sensing receptor (CaR) in normal colorectal mucosa (calcium: +27%, p=0.03; vitamin D3: +39%, p=0.01). Vitamin D3 alone was most effective at upregulating CYP27B1 (the enzyme that activates vitamin D locally). Supports the biological plausibility of calcium’s protective role.

Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. Nutr Cancer. 2009;61(1):47-69. Funding provided by the National Dairy Council.

Karavasiloglou N, Hughes DJ, Murphy N, et al. Prediagnostic serum calcium concentrations and risk of colorectal cancer development in 2 large European prospective cohorts. Am J Clin Nutr. 2023 Jan;117(1):33-45. Found serum ionized calcium was inversely associated with CRC risk, particularly in the colon; not relevant for intakes since no link between calciums intakes and ionized calcium.

Kato I, Sun J, Hastert TA, Abrams J, Larson JC, Bao W, Shadyab AH, Mouton C, Qi L, Warsinger Martin L, Manson JE. Association of calcium and vitamin D supplementation with cancer incidence and cause-specific mortality in Black women: Extended follow-up of the Women’s Health Initiative calcium-vitamin D trial. Int J Cancer. 2023 Sep 1;153(5):1035-1042. Abstract only. Found no benefit of calcium for black women.

Papier K, Bradbury KE, Balkwill A, et al. Diet-wide analyses for risk of colorectal cancer: prospective study of 12,251 incident cases among 542,778 women in the UK. Nat Commun. 2025 Jan 8;16(1):375. Supplementary material available.

Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006; 354:684–696. No supplementary material found.

World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and colorectal cancer. Available at dietandcancerreport.org

Zhang X, Keum N, Wu K, Smith-Warner SA, Ogino S, Chan AT, Fuchs CS, Giovannucci EL. Calcium intake and colorectal cancer risk: Results from the nurses’ health study and health professionals follow-up study. Int J Cancer. 2016 Nov 15;139(10):2232-42. Supplementary material available.

Zouiouich S, Wahl D, Liao LM, Hong HG, Sinha R, Loftfield E. Calcium Intake and Risk of Colorectal Cancer in the NIH-AARP Diet and Health Study. JAMA Netw Open. 2025 Feb 3;8(2):e2460283. Supplementary content available.